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  Since its ﬁ  rst application in 1995, the score has 
increasingly been used as a primary or secondary 
endpoint in multi-centre placebo-controlled trials 
(10  –  13). Beyond the established role of the ALS-
FRS-R in a trial setting there has been a growing use 
of the score for the assessment of ALS symptoms 
during the course of the disease and for clinical 
decision-making (14). Migration of ALSFRS-R 
assessment from the clinical setting (in-clinic) to an 
online data capturing system has the potential to 
improve clinical encounters, provide context to 
patients on their progress, and evaluate their needs 
in their own home and at a time of their choosing 
rather than subject to the scheduling of their health-
care provider. Here we report the results of a pro-
spective controlled study of ALSFRS-R in-clinic 
compared with online self-assessment. We hypothe-
sized that because the self-reported ALSFRS-R has 
been shown to be reliable by patients, caregivers, and 
even over the phone, the use of online data entry 
    Introduction 
  The ALS Functional Rating Scale (ALSFRS) is a 
validated, clinician-administered instrument for 
assessment in the domains of gross and ﬁ  ne motor 
function, bulbar symptoms and breathing ability in 
patients with ALS (1). The score reﬂ  ects deteriora-
tion of function in the natural course of ALS but 
may have lower sensitivity in advanced disease 
stages (2,3). The scale was developed primarily to 
assess outcomes in pharmaceutical clinical trials and 
does not rely upon physical examinations or instru-
ments (1,4). An initial imbalance within the scale 
that minimized the importance of respiratory func-
tion was rectiﬁ  ed by a revision (ALS Functioning 
Rating Scale, revised (ALSFRS-R)) to incorporate 
respiratory symptoms and the need for ventilation 
(5). When administered as an interview, the ALS-
FRS-R shows a high inter-rater and intra-rater reli-
ability (6,7) and can be reliably administered over 
the telephone (7  –  9). 
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would not degrade the quality of the data. We also 
sought to explore the time and physical burden to 
patients of collecting data online to establish feasibil-
ity of online monitoring methods. Because regular 
assessment of inevitably declining physical function 
might have adverse psychological consequences for 
patients we also sought to explore the emotional bur-
den of participating in the site.     
  Methods   
  Study protocol and IT infrastructure 
  We designed a prospective single-centre clinical 
study to evaluate the feasibility and reliability of 
online self-assessment. The protocol encouraged 
clinician-conﬁ  rmed patients with possible, probable 
or deﬁ  nitive ALS (El Escorial criteria) (15) to visit 
the website weekly over a 52-week period. Each 
patient determined a week day on which to perform 
his or her weekly self-assessment using patient 
reported outcomes (PROs). In order to measure 
the inherent appeal of returning to the site 
unprompted, patients did not receive a reminder, 
e.g. by telephone, e-mail or text message. PROs 
included the ALSFRS-R, the ALS Assessment 
Questionnaire (ALSAQ-40) (16), the Council on 
Nutrition Appetite Questionnaire (CNAQ) (17) 
and two self-reporting assessments of dyspnoea 
(Borg  ’  s scale CR10, CDS) (18,19); data on these 
instruments will be reported separately at a later 
date. Subsequently, the ethics review committee 
and Data Security Ofﬁ  cer approval was obtained 
(Ethikkomission der Charit  é   - Universit  ä  tsmedizin 
Berlin, Charit  é  platz 1, 10117 Berlin). We created 
the web-based application www.ALShome.de for 
data capture, a related database for storage and a 
content management system (CMS) for the admin-
istration and analysis of PRO measurements includ-
ing the ALSFRS-R. The internet application www.
ALShome.de and the CMS were developed in the 
programming language C Sharp (C#). Data are 
stored on a Microsoft  ®   SQL database located on a 
secure internal server at the university data centre. 
The CMS allows for website management includ-
ing the administration of PRO measurements, data 
export for further analysis and adjustment of web 
visit protocols at each time-interval.     
  Patients and data collection 
  Between 2 February 2010 and 2 February 2011, 162 
of 443 ALS patients seen at the Department of Neu-
rology at the Charit  é   University Hospital of Berlin 
gave written consent for the trial in accordance with 
the Declaration of Helsinki. Lack of internet access 
and the refusal to participate were the most common 
reasons for non-attendance. One hundred and forty-
four patients completed at least one online assess-
ment (89%). We excluded 17 patients from the 
analysis due to protocol deviation as more than four 
weeks had elapsed from on-site to online assessment. 
In-clinic FRS assessment was collected via tablet PC 
administered by a nurse. Thus, in 127 patients (78%) 
we obtained a complete set of in-clinic assessment 
followed by online assessments, at baseline. The 
mean interval between online and on-site visits was 
8.8 days (SD 6.3). The on-site follow-up data were 
captured from 108 patients (85% of baseline) at a 
visit that was, on average, 3.5 months later (SD 1.7). 
In 81 patients (50% of all patients included in the 
study) we obtained both forms of assessment at two 
time-points (Figure 1). 
  In addition, the patient was asked questions 
about who ﬁ   lled in the questionnaire (patient or 
caregiver), the time burden on the patient, and the 
physical and emotional strain of periodic online self-
assessment, rated with a single-item   ‘  none  ’  ,   ‘  low  ’  , 
  ‘  moderate  ’  , or   ‘  high  ’   response scale.      
  Data analysis 
  Data were analysed with IBM SPSS Statistics ver-
sion 19.0.0.1 for Macintosh. Results were expressed 
    Figure 1.         Flow chart of whole ALSFRS-R self-assessment study within one year.   212     A. Maier et al.   
as means (      SD) if normally distributed and medi-
ans (maximum/minimum) if distribution was non-
Gaussian. Correlational analysis was performed with 
Spearman  ’  s rho because of the ordinal nature of the 
ALSFRS-R. A statistically signiﬁ  cant difference of 
paired samples was analysed with a   t-  test. The dif-
ference plot method (20) by Bland and Altman was 
used for analysing agreement. A value of   p       0.01 
(two-tailed) was considered signiﬁ  cant.       
  Results 
  One hundred and twenty-seven patients (described 
in Table I) met the conditions for statistical analysis 
according to study protocol. The mean ALSFRS-R 
on-site at baseline was 33.6 (SD 9.1) compared to 
33.8 (SD 9.1) online. The mean loss of the ALS-
FRS-R value per month (modiﬁ  ed delta ALSFRS-R: 
48   –   ALSFRS-R at   ‘  time of inclusion  ’  /duration from 
onset to inclusion) at baseline was 0.77 (SD 0.79), 
which is slightly slower progression than has been 
reported in other ALS studies (0.81, 48   –   ALSFRS-R 
at   ‘  time of diagnosis  ’  /duration from onset to diagno-
sis) (21). Despite the curvilinear progression of ALS 
(22), this calculation method is based on a simpliﬁ  ed 
linear progression model of ALS. Median time since 
symptom onset at baseline was 23 months. After 3.5 
months the mean follow-up on-site ALSFRS-R was 
31.9 (SD 8.7) compared to online 31.8 (SD 8.7). 
Correlation between baseline and ﬁ  rst online ALS-
FRS-R was very high with a coefﬁ   cient of 0.96 
(  p        0.001) (Figure 2). 
  Agreement between both data-capture methods 
was very high (Figure 3). The distribution of differ-
ences was normal, suggesting there was no system-
atic directional bias to any differences. The mean 
difference (bias) was   –  0.18 and the upper and lower 
limits of agreement were 4.4 and   –  4.7, respectively. 
More than 95% of all pairs of measurement were 
within the limits of agreement. 
  A similarly high degree of correlation also existed 
between the in-clinic follow-up visit and the closest 
online ALSFRS-R to this visit (0.965;   p       0.001; 
    Table I. Characteristics of patient population (  n       127)  at 
baseline.    
Mean age (SD; min/max) 58.0 (9.9; 35/82)
Site of onset (%)
     Limb
     Bulbar
     Respiratory
    73
    24
    3
Sex (%) M: 90 (71%)
    F: 37 (29%)
Median months since ﬁ  rst symptom onset 
(min/max)
23.0 (1/141)
Mean ALSFRS-R baseline in-clinic (SD) 33.6 (9.1)
Mean loss of ALSFRS-R value per month 
(Delta) at baseline in-clinic (SD)
0.77 (0.79)
    Figure 2.         Correlation between baseline in-clinic ALSFRS-R and ﬁ  rst online ALSFRS-R (  n        127, correlation coefﬁ  cient      0.96; 
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    Figure 3.         Bland-Altman plot of ALSFRS-R baseline in-clinic and ﬁ  rst online assessment (  n       127, mean difference       –  0.18; limits of 
agreement 4.4 and   –  4.7).   
    Figure 4.         Bland-Altman plot of ALSFRS-R follow-up and closest online ALSFRS-R (  n        81, mean difference        0.06; limits of 
agreement 4.3 and   –  4.2).   214     A. Maier et al.   
  n       81). In the Bland-Altman plot for follow-up visits 
(Figure 4), the mean difference was 0.06 and upper 
and lower limits of agreement were 4.3 and   –  4.2. 
Again, more than 95% of the data were within the 
limits of agreement. These data also suggest very 
good agreement in follow-ups. 
  Based on the additional question   “  who ﬁ  lled in 
the questionnaire  ”  , 22.4% of online surveys were 
completed by a caregiver. There was a high correla-
tion between the self-administered baseline ALS-
FRS-R data and those of the two online groups, with 
values of 0.95 for the self-administered group 
(  n        86) and 0.92 for the caregiver-assisted group 
(  n        21) with   p        0.01. With the Bland-Altman 
method, no relevant bias was detected in the two 
groups (data not shown). 
  Eleven percent of the patients who gave written 
consent did not complete their online assessment at 
all. There was no statistically signiﬁ  cant bias accord-
ing to age, disease duration or ALSFRS-R. Only a 
trend can be seen in gender, as there was a higher 
percentage of women in the group of non-completers 
compared to completers (50% vs. 29%,   p       0.075). 
  Table II shows the report on time burden, phys-
ical limitation and emotional strain of online self-
assessment. When interviewed about the time 
burden and the emotional and physical strain, more 
than 95% of the patients who ﬁ  lled in the surveys 
felt that they were  ‘  not at all ’   or only  ‘  slightly  ’   affected 
by online self-assessment. Three months on, no 
signiﬁ  cant change was observed (Table III:   t  -test, 
  p       0.1).    
  Discussion 
  We found very high correlations between ALSFRS-R 
scores at two time-points administered in-clinic 
compared to through the internet. There was no evi-
dence of systematic bias towards higher or lower 
scores online. We also found that patients did not 
consider online ALSFRS-R entry to be physically or 
emotionally burdensome, or to be time-consuming. 
We propose for future development that a time-span 
between online assessments adapted to a given 
patient  ’  s rate of progression could be even more efﬁ  -
cient. Completing PROs online could be a way to 
complement face-to-face visits and manage care in 
a more personalized and needs-based way, rather 
than relying upon regular time-intervals such as 3- or 
6-month follow-up appointments. Online PROs 
could also be used to improve the convenience and 
thereby participation in clinical trials that use the 
ALSFRS-R as an endpoint. 
  Our ﬁ  ndings must be considered in the context 
of their limitations. The original ALSFRS-R was 
designed as a paper-based clinician interview rather 
than a patient self-report measure, let alone one 
measured through the internet. However, other stud-
ies have found no evidence that self-report (23), 
caregiver report, or telephone administration signiﬁ  -
cantly degrades the quality of the scores. Further-
more, the nature of the measure (12 items 
comprising short, clear questions with well-deﬁ  ned 
anchor points for response options) means that there 
is very little difference in user experience between 
the paper-pencil method and computerized admin-
istration. The move from paper-based PROs (pPROs) 
to electronic PROs (ePROs) (24) has prompted a 
number of similar studies to establish equivalence 
between the two methods in various medical indica-
tions and psychometric tests (25  –  28). On the whole, 
our population was relatively early in its disease 
course and it is unclear how its ability to respond 
online, or the perceived burden of the ALSFRS-R, 
would be felt at later stages of the disease   –   it is 
plausible that as physical function deteriorates the 
physical burden would increase to the point that data 
entry would be difﬁ   cult or impossible. However, 
these patients also ﬁ  nd attendance at clinic difﬁ  cult, 
and there are numerous adaptations available to 
operate a computer, such that online data collection 
may actually increase the representativeness of data 
that can be collected from clinical centres. 
  A further limitation was that 11% of the patients 
who gave written consent did not complete their 
online assessment at all. We could not show a 
    Table II. Time burden, emotional and physical strain connected with online self-assessment on www.ALShome.de at baseline. 
  n       112.   
Question None Low Moderate High Total
Time burden 82/82.1% 17/15.2% 2/1.8% 1/0.9% 112/100%
Emotional strain 88/78.6% 19/17.0% 4 /3.6% 1/0.9% 112/100%
Physical strain 93/83.0% 16/14.3% 2/1.8% 1/0.9% 112/100%
    Table III. Time burden, emotional and physical strain connected with online self-assessment on www.ALShome.de at follow-up. 
Follow-up visit after 97.3 days (SD 51.7).   n       78.  
Question None Low Moderate High Total
Time burden 63/80.8% 12/15.4% 2/2.6% 1/1.3% 78/100%
Emotional strain 61/78.2% 12/15.4% 4/5.1% 1/1.3% 78/100%
Physical strain 62/79.5% 8/10.3% 5/6.4% 3/3.8% 78/100%     Comparison of online ALSFRS-R with in-clinic evaluation      215
systemic bias in this group, but it cannot be excluded 
that factors such as insufﬁ  cient technical require-
ments or discomfort with submitting data online 
have inﬂ   uence. Finally, our population was pre-
dominantly urban, seen at a specialist centre, and 
located in a technologically advanced country; our 
ﬁ  ndings may not generalize readily to other popula-
tions and the issue of the   ‘  digital divide  ’   should be 
kept in mind. 
  Outside clinical practice, online administration of 
PROs has been in use for ALS patients since 2006 
at the social internet platform www.patientslikeme.
com. Use of the ALSFRS-R has included an exten-
sion to the scale for more disabled patients (3) and 
even a clinical observational study to test the effect 
of lithium on ALS progression (29). However, such 
online assessment preceded validation that collecting 
outcome data was viable and valid from patients with 
a clinically conﬁ  rmed diagnosis; this study has ful-
ﬁ  lled this important foundational step. 
  An internet-based assessment of ALSFRS-R 
may facilitate patient follow-up in the home care 
environment. This methodical approach contributes 
to greater density and continuity in the collection of 
outcomes that otherwise would not be possible to 
achieve. At the same time, it may save time and 
reduce costs by integrating online data into the 
workﬂ   ow of clinic visits. Hence, this online self-
assessment is a welcome addition to an electronic 
Case Report Form (eCRF), the most common tool 
for data collection in clinical trials. Dividing the 
internet-submitted FRS score into its component 
subscores (e.g. speech, walking, arm/hand, respira-
tory, swallowing) could also support clinicians to 
estimate the progress of individual symptoms and 
time their interventions in a needs-based manner. 
For instance, the fall of the respiratory subscore 
beneath a critical threshold may indicate the need 
for timely consultation. 
  In general, the use of patient-reported outcomes 
(PRO) such as ALSFRS-R has become more wide-
spread in recent years, particularly in trials dealing 
with chronic disabling diseases (30,31). In compli-
ance with the FDA standards (32), PROs supple-
ment objective measures or replace them, especially 
if there is a lack of biomarkers or surrogate endpoints 
as in ALS. Apart from clinical trials, PRO measure-
ments are aimed at improving patient care by inten-
sifying the patients  ’   involvement and considering 
their perspective on the disease. A study of Patient-
sLikeMe  ’  s users suggested better health literacy and 
communication with their healthcare providers as a 
result of tracking their progress with PROs (33). Our 
study supports the notion that online self-assessment 
is a practicable way to integrate the patient in man-
aging their care. 
  Future research should establish and quantify the 
potential for resource savings and improved patient 
outcomes in incorporating online data collection 
into clinical management.                     
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